Chronic hepatitis C: A clinical overview

Cleveland Clinic Journal of Medicine

Volumn 64, Issue 5, 1997, Pages 259-268

  Younossi, Zobair M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

CHRONIC HEPATITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; IMMUNITY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; REVIEW; RISK FACTOR; SIDE EFFECT;

EID: 0030906235     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.64.5.259     Document Type: Review

References (48)

1. Alter HJ. To C or not to C: these are the questions. Blood 1995; 85:1681-1695.
2. Younossi ZM, McHutchison JG. Serological test for HCV infection. Viral Hepatitis Review 1996; 2:161-173.
3. Bukh J, Miller RM, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15:41-63.
4. Esteban JI, Genesca J, Alter HJ. Hepatitis C: Molecular biology, pathogenesis, epidemiology, clinical features and prevention. Prog Liver Dis 1992; 10:253-282.
5. Cerney A, McHutchison JG, Pasquinelli C, et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA-A2.1 binding motif. J Clin Invest 1995; 95:521-530.
6. Cerney A, Chisari FV. Immunological aspect of HCV infection. Intervirology 1994; 37:119-125.
7. Alter MJ, McQuillan GM, Everhart JE. Viral hepatitis. In: Everhart EJ, ed. Digestive diseases in the United States: epidemiology and impact. Bethesda, MD: US Dept. of Health and Human Services, 1994:125-156.
8. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995; 15:5-14.
9. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23:437-455.
10. Lanphear BP, Linnemann CC Jr, Cannon CG, DeRonde MM, Pendy L, Kenley LM. Hepatitis C virus infection in health care workers: Risk of exposure and infection. Infect Control Hosp Epidemiol 1994 15:745-750.
11. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Semin Liver Dis 1995; 15:64-69.
12. Sallie R, Di Bisceglie AM. Viral hepatitis and hepatocellular carcinoma. Gastroenterol Clin North Am 1994; 23:567-579.
13. Davis GL, Lau JYN, Lim HL. Therapy for chronic hepatitis C. Gastroenterol Clin North Am 1994; 23:603-613.
14. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 1993; 88:240-243.
15. Koff RS, Dienstag JL. Extrahepatic manifestations of hepatitis C and association with alcoholic liver disease. Semin Liver Dis 1995; 15:101-109.
16. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis: looking back in the second decade. Ann Intern Med 1993; 119:110-115.
17. Esteban JI, Lopez-Talavera JC, Genesca J, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991; 115:443-449.
18. de Franchis R, Meucci G, Vecchi M, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993; 118:191-194.
19. Chemello L, Cavalletto L, Noventa F, et al. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-a. J Viral Hepatitis 1995; 2:91-96.
20. Serfaty L, Giral P, Loria A, Andreani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994; 21:12-17.
21. Lau J YN, Davis G, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C (published erratum appears in Lancet 1993;243:504). Lancet 1993; 341:1501-1504.
22. De Medina M, Schiff ER. Hepatitis C: diagnostic assays. Semin Liver Dis 1995; 15:33-40.
23. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994; 21:1-3.
24. Marcellin P, Martinot M, Pouteau M, et al. HCV genotype and pre-treatment serum HCV RNA level are the main and independent prognosis factors of sustained response to interferon in chronic hepatitis C [abstract]. Hepatology 1994; 20:445.
25. Gretch D, Corey L, Wilson J, et al. Assessment of hepatic C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. J Infect Dis 1994; 169:1219-1225.
26. Davis GL, Lau JYN, Urdea MS, et al. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994; 19:1337-1341.
27. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis 1995; 15:70-81.
28. Camma C, Craxi A, Tine F, et al. Predictors of response to alpha-interferon (IFN) in chronic hepatitis C: A multivariate analysis on 361 treated patients [abstract]. Hepatology 1994; 20:348.
29. Maddrey WC, Alter H, Davis G, et al. Consensus on HCV testing and treatment. National Hepatitis Detection and Treatment Program. 1992.
30. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recomhinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989; 321:1501-1506.
31. Marcellin P, Boyer N, Giostra E, et al. Recombinant human a-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13:393-397.
32. Fired MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995; 15:82-91.
33. Johnson HM, Bazer FW, Szente BE, Jarpe MA. How interferon fights disease. Sci Am 1994; 270(5):68-75.
34. Lin R, Schoeman MN, Craig PI, et al. Can the response to interferon treatment be predicted in patients with chronic active hepatitis C? Aust NZ J Med 1991; 21:387-392.
35. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991; 101:497-502.
36. Tabone M, Galatola G, Secreto P, Marini C, Molinaro G, Arico S. Serum levels of anti-hepatitis C virus IgM core antibodies may predict the response to interferon-a therapy in chronic hepatitis C. J Viral Hepatitis 1994; 1:155-157.
37. Pagliaro L, Craxi A, Cammara C, et al. Interferon-a for chronic hepatitis C: analysis of pretreatment clinical predictors of response. Hepatology 1992; 19:820-828.
38. Lau JYN, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341:1501-1504.
39. Okada SI, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992; 16:619-624.
40. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323:295-301.
41. Jakiche A, Saletta M, Kaur S, Barnes D, Carey WD. Prednisone pre-treatment does not enhance efficacy of Interferon in treatment of chronic viral hepatitis C [abstract]. Gastroenterology 1996; 110:A1221.
42. Kugelmas M, Yen-Lieberman B, Tuthill RJ, Carey WD. Combination therapy achieves biochemical but not virological or histological response in interferon-resistant hepatitis C [abstract]. Hepatology 1995; 22:1343.
43. Desai TK. Phlebotomy teduces transaminase levels without inducing iron deficiency in patients with chronic hepatitis C [abstract]. Hepatology 1995; 22:1207.
44. Swanson NR, Prins A, Lareu RR, et al. The role of iron indices in predicting response to interferon in cases of CHC with known genotype [abstract]. Hepatology 1995; 22:296.
45. Yano M, Kakumu S, Hayashi H, Takikawa T, Nishimura N. Phlebotomy followed by a-interferon therapy in patients with chronic hepatitis C [abstract]. Hepatology 1995; 22:119A.
46. Brillanti S, Garson J, Fill M, et al. A pilot study of combination therapy with ribavirin plus Interferon-alpha for Interferon-alpha resistant chronic hepatitis C. Gastroenterology 1994; 1078:812-817.
47. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C: A randomized double-blind placebo controlled trial. Ann Intern Med 1995; 123:897-903.
48. Terrault NA, Wright TL. Hepatitis C virus in the setting of transplantation. Semin Liver Dis 1995; 15:92-100.